OR WAIT 15 SECS
Volume 13, Issue 10
The companies collaborated to launch a new cell-based profiling service for biochemical assay.
Reaction Biology Corporation (RBC), a provider of drug discovery services, and Promega, a supplier of life science products, announced a new cell-based profiling service for drug discovery on Sept. 24, 2018, which is expected to enhance the prioritization of compounds earlier in the research stage.
The new service, based on Promega NanoBRET technology, measures direct target engagement of more than 50 kinases in live cells without disrupting the integrity of the cellular membrane and will be expanded to cover more than 200 kinases in the future.
“Our customers have been looking for a cell based service to confirm the biochemical assay data we provide,” said Haiching Ma, RBC’s chief science officer, in a company press release. “Finally, with the NanoBRET service, they can look at highly relevant cell-based results. The Promega assay is unique in cell-based discovery.”
“Biochemical kinase assays are a piece of the puzzle, but don’t tell the whole story,” said Matt Robers, Promega senior research scientist, in the press release. “By incorporating cellular assays at an earlier stage, researchers can get a better understanding of the impacts of live-cell physiology on the potency and selectivity of their compound. This could save development time and advance chemical matter that has a better chance of having cellular efficacy. Researchers have been seeking these more kinase-specific cell-based assays at service providers, and RBC’s assay optimization expertise and excellent reputation as a service provider make them the logical choice.”
Promega and RBC launched the new service at the Discovery On Target conference in Boston, MA on September 25–28, 2018.
Source: Reaction Biology